Anixa Biosciences and its partner Moffitt Cancer Center have initiated treatment of the first subject in the Phase I clinical trial of new chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
The dose-escalation trial will assess the safety and the maximum tolerated dose of follicle stimulating hormone receptor T-cells.
Moffitt Cancer Center is carrying out the trial, which will also evaluate the efficacy of the therapy in up to 48 subjects.
The CAR-T method utilised for the company’s therapy is called chimeric endocrine receptor T-cell (CER-T), as the engineered T-cells’ target is an endocrine receptor.
Anixa holds the exclusive, global license to this new technology.
This CER-T therapy varies from standard CAR-T as it acts on the follicle stimulating hormone receptor (FSHR), which was found in research to be specifically expressed on ovarian cells in healthy adult females.
Anixa Biosciences chairman and CEO Amit Kumar said: “We are pleased that the first patient has been treated in our ovarian cancer CAR-T clinical study.
“This is truly an exciting time for Anixa, as we have now begun treating patients in our second clinical trial.
“With our CAR-T study, we hope to determine whether our unique targeting approach will work in solid tumours, a difficult challenge for traditional CAR-T therapies.”
A clinical-stage biotech firm, Anixa has various programmes for cancer and infectious diseases.
Its therapeutic portfolio comprises a cancer immunotherapy programme using CER-T technology, being developed along with Moffitt Cancer Center and MolGenie.
The portfolio of the company comprises a new vaccine being developed along with the Cleveland Clinic for breast cancer prevention, as well as a vaccine for preventing ovarian cancer.
Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.